David Yardeni
Overview
Explore the profile of David Yardeni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yardeni D, Hitawala A, Howard L, Heller T, Waldman M
J Clin Transl Hepatol
. 2024 Sep;
12(9):759-760.
PMID: 39280066
No abstract available.
2.
Etzion O, Bareket-Samish A, Yardeni D, Fishman P
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672201
Namodenoson (CF102) is a small, orally available, anti-inflammatory, and anti-cancer drug candidate currently in phase 2B trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; formerly known as non-alcoholic steatohepatitis...
3.
Saadi R, Saban A, Weintraub A, Yardeni D, Eshkoli T
Arch Gynecol Obstet
. 2024 Feb;
310(1):427-432.
PMID: 38355761
Objective: To assess the association between aspartate aminotransferase (AST) to platelet count ratio index (APRI score), during the first and third trimesters of pregnancy and the development of intrahepatic cholestasis...
4.
Makarenkov N, Yoel U, Haim Y, Pincu Y, Bhandarkar N, Shalev A, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38255963
Circulating miRNAs are increasingly being considered as biomarkers in various medical contexts, but the value of analyzing isomiRs (isoforms of canonical miRNA sequences) has not frequently been assessed. Here we...
5.
Yardeni D, Shiloh A, Lipnizkiy I, Nevo-Shor A, Abufreha N, Munteanu D, et al.
Sci Rep
. 2023 Dec;
13(1):22113.
PMID: 38092876
Portal hypertension often precedes the development of advanced fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) and may accelerate disease progression to cirrhosis. We aimed to evaluate whether...
6.
Abu-Freha N, Abu-Kosh O, Yardeni D, Ashur Y, Abu-Arar M, Yousef B, et al.
Life (Basel)
. 2023 Sep;
13(9).
PMID: 37763276
There is accumulating evidence that treatment of chronic hepatitis C (HCV) leads to improvements in liver fibrosis. We aimed to investigate the improvement in fibrosis stage following treatment with direct-acting...
7.
Abu-Freha N, Cohen B, Gordon M, Weissmann S, Fich A, Munteanu D, et al.
Biomedicines
. 2023 May;
11(4).
PMID: 37189727
(1) Background: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. Aims: We aimed to investigate the frequency of comorbidities and malignancies among NAFLD patients compared to the general...
8.
Etzion O, Hamid S, Lurie Y, Gane E, Yardeni D, Duehren S, et al.
Hepatology
. 2023 Feb;
77(6):2093-2103.
PMID: 36800850
Background And Aims: HDV infection leads to the most aggressive form of human viral hepatitis for which there is no FDA-approved therapy. PEG IFN-lambda-1a (Lambda) has previously demonstrated a good...
9.
Shingina A, Chadha R, Lim N, Pillai A, Vodkin I, Montenovo M, et al.
Liver Transpl
. 2023 Feb;
29(6):591-597.
PMID: 36745932
We conducted a web-based survey to characterize liver transplant (LT) evaluation and listing practices for patients being evaluated for combined heart-liver transplantation (CHLT), with a specific emphasis on patients with...
10.
Yardeni D, Yang A, Heller T, Koh C
J Viral Hepat
. 2023 Feb;
30(5):464-465.
PMID: 36740889
No abstract available.